Objective. To compare the efficacy, safety, and tolerability of once-daily administration of
modified-release methylphenidate (MPH MR) with placebo in children with attention …

Objective: The aim of this study was to evaluate dose–response characteristics in
adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with once-daily …

Objective: To explore treatment response to Osmotic Release Oral System®(OROS)
methylphenidate in children with ADHD with and without comorbid learning disability (LD) …

Objective: The aim of this study was to assess the effectiveness and tolerability of a long-
acting methylphenidate (MPH) formulation, beaded MPH (B-MPH), for treatment of attention …

Abstract Objective: This 5-week, multicenter, double-blind, placebo-controlled, parallel-
group investigation is the first fixed-dose study to evaluate efficacy and tolerability of three …

OBJECTIVE:: The efficacy and safety of dexmethylphenidate extended release (d-MPH-ER)
was compared to placebo in pediatric patients with attention-deficit/hyperactivity disorder …

This 8-week, open-label extension of a double-blind study reports on safety data for 171
adolescents with attention-deficit/hyperactivity disorder (ADHD) who received once-daily …

OBJECTIVE: Few treatment studies of attention-deficit/hyperactivity disorder (ADHD) extend
beyond a few months. This article reports an interim analysis of a 24-month study evaluating …

Objective: A preliminary study to examine the efficacy of osmotic-release oral system
(OROS) methylphenidate for attention-deficit/hyperactivity disorder (ADHD) symptoms and …

Objective: To evaluate the safety and efficacy of extended-release methylphenidate with a
bimodal profile using SODAS™ technology (Ritalin® LA™) compared with placebo in …